The IPA has been informed that Spark Therapeutics has realigned its portfolio and made the difficult decision to stop its Pompe program. This includes the Phase 1/2 Investigational Gene Transfer Study, Resolute, for Adults with Late-Onset Pompe Disease (LOPD).
A statement from Spark will be issued to our community soon.